What the Laboratory Can and Cannot Conclude

The pattern in the guided case supports a focused MDS workup because it combines persistent cytopenias, macrocytosis, concerning smear features, marrow dysplasia above the recommended threshold, low blasts, ring sideroblasts, and clonal findings. It does not independently establish a final MDS subtype. Classification must integrate specimen adequacy, exclusions, morphology, blast assessment, cytogenetics, molecular results, and the chosen framework.

WHO-HAEM5 and ICC are current named frameworks, but they use different terminology and differ in selected genetics-defined entities. A biallelic TP53 alteration means both working copies of TP53 are affected, for example by two mutations or by one mutation plus loss of the other copy. Copy-neutral loss of heterozygosity means one parental copy is lost and the remaining copy duplicated, so the copy count can look unchanged while genetic diversity is lost. These are controlled molecular-pathology determinations, not worksheet labels.

The deciding endpoint is qualified hematopathology review under the current controlled classification procedure, integrating marrow adequacy, blast assessment, morphology, iron stain, cytogenetics, molecular findings, and documented mimics.